65
Participants
Start Date
October 31, 2012
Primary Completion Date
March 31, 2013
Study Completion Date
August 31, 2014
Rivaroxaban
Patients will continue on their Rivaroxaban dose as previously prescribed by their individual physician. No dose adjustments will be made for the purpose of this study.
no anticoagulation
Carolina Point II, Chapel Hill
University of North Carolina, Chapel Hill
OTHER